Sphere graphic

How Our Testing Process Works

Convenient. Guided. Reliable. The way testing should be.
1. Answer a few questions

Complete our CDC Questionnaire to tell us about your symptoms and exposure.

2. Get a Prescribed Order

An eMed Healthcare Partner will determine if the test is right for you and issue a prescribed order.

3. Delivery or Pick-Up

The test is shipped within 24 hours, or pick it up locally.

4. Test at Home

Have a virtual visit guided by an eMed Certified Guide.

5. Get Results in 15 Minutes

Receive follow-up healthcare instructions and a digital pass, if your COVID-19 test is negative.

Learn More

Use the links below to learn more about Abbott's BinaxNOW COVID-19 Ag Card Home Test.

See FDA Emergency Use Authorization

Abbott BinaxNOW COVID-19 Ag Card Home Test

What’s in the Box

The shortest route to fast results

Inside, you’ll find all you need to conduct a rapid COVID-19 test, authorized for use on a virtual visit with an eMed Certified Guide.

Test Card
shape-3

BinaxNOWTM
COVID-19 Ag Card

Reagent Bottle
shape-2

Newly Designed Single-Use
Extraction Reagent Bottle

Swab
Nasal swab

Nasal Swab

The eMed Advantage

Authorized

We partner with leading manufacturers of government-authorized or approved tests.

At-Home Testing

Our digital point-of-care solution guides you through the test with live video guidance, ensuring proper test procedure and validated results.

Rapid results

Results are available within minutes of taking the test.

Digital Pass

Users who test negative receive a digital pass, enabling them to return to activities, while still following appropriate safety protocols.

  • This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA;
  • This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and,
  • This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.